Development of second-generation probiotics as radiation mitigators

开发第二代益生菌作为辐射缓解剂

• 批准号: 10593033
• 负责人: CLAUDE ROGERS
• 金额: $ 148.63万
• 依托单位: CHROMOLOGIC, LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-16 至 2023-03-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10593033
• 关键词: Acute; Animal Model; Animals; Biological Markers; Development; Generations; In Vitro; Interferon-beta; Lactobacillus reuteri; Mus; Probiotics; Radiation Syndromes; Safety; Technology; Universities; Wisconsin; base; cytokine; design and construction; efficacy testing; gastrointestinal; interleukin-22; prevent; radiation mitigator

The University of Pittsburgh and the University of Wisconsin have developed a Lactobacillus reuteri-based cytokine delivery platform (LRC-DP) to mitigate acute gastrointestinal radiation syndrome (GI-ARS) and has licensed this technology to ChromoLogic. ChromoLogic has developed a LRC-DP construct that produces the cytokines IL-22 or IFN-β and plans to test efficacy in animal models of GI-ARS.

匹兹堡大学和威斯康星大学开发了一种基于罗伊氏乳杆菌的细胞因子递送平台（LRC-DP），以减轻急性胃肠道辐射综合征（GI-ARS），并已将该技术授权给ChromoLogic。ChromoLogic公司开发了一种LRC-DP构建物，可产生IL-22或IFN-β细胞因子，并计划在GI-ARS动物模型中测试其功效。